Charles River Laboratories International Inc (NYSE: CRL) open the trading on Thursday, with great promise as it jumped 3.27% to $223.47, before settling in for the price of $216.39 at the close. Taking a more long-term approach, CRL posted a 52-week range of $91.86-$228.88.
The Healthcare sector firm’s twelve-monthly sales growth has been -47.65% for the last half of the decade. Meanwhile, its Annual Earning per share during the time was -47.65%. Nevertheless, stock’s Earnings Per Share (EPS) this year is -0.76%. This publicly-traded company’s shares outstanding now amounts to $49.22 million, simultaneously with a float of $48.64 million. The organization now has a market capitalization sitting at $11.00 billion.
Charles River Laboratories International Inc (CRL) Ownership Facts and Figures
Sometimes it helps to make our mind if we keep our tabs on how bigger investors are working with the stock of the Diagnostics & Research industry. Charles River Laboratories International Inc’s current insider ownership accounts for 1.17%, in contrast to 104.68% institutional ownership. Preceding that transaction, on Aug 18 ’25, Company’s EVP, Corp Strategy & Develop sold 800 for 157.60, making the whole transaction’s value amount to 126,080. This particular insider is now the holder of 24,116 in total.
Charles River Laboratories International Inc (CRL) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of 2.59 per share during the current fiscal year.
Charles River Laboratories International Inc’s EPS decrease for this current 12-month fiscal period is -0.76% and is forecasted to reach 11.00 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will increase by 5.40% through the next 5 years, which can be compared against the -47.65% growth it accomplished over the previous five years trading on the market.
Charles River Laboratories International Inc (NYSE: CRL) Trading Performance Indicators
Let’s observe the current performance indicators for Charles River Laboratories International Inc (CRL). It’s Quick Ratio in the last reported quarter now stands at 1.10. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 2.73. Similarly, its price to free cash flow for trailing twelve months is now 20.23.
In the same vein, CRL’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -1.55, a figure that is expected to reach 2.35 in the next quarter, and analysts are predicting that it will be 11.00 at the market close of one year from today.
